Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), and its CRDMO arm Aurigene Pharmaceutical Services Limited (Aurigene), today announced that they have signed a non-binding Memorandum of Understanding (MoU) with Kainomyx, Inc., a US-based company with a proprietary platform that helps target cytoskeletal proteins of parasites, a novel mechanism of action for the development and commercialization of affordable anti-malarial drug in in the U.S., Europe, and in low and middle-income countries. The MoU remains subject to signing of a definitive agreement.
Read MoreAurigene Pharmaceutical Services Limited (Aurigene), a global contract research, development, and manufacturing services organization (CRDMO), will provide discovery services to Edity Therapeutics Limited (Edity) in cell therapy. Dr. Reddy’s Laboratories Limited, Aurigene’s parent company, recently made a strategic investment in Edity, a biotechnology company based in Israel.
Read MoreAurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with process & analytical development and small scale manufacturing of antibodies and other recombinant proteins for preclinical and early phase clinical requirements. The process and analytical development laboratories are now operational while the commissioning of manufacturing capacity will be completed later in 2024.
Read MoreAurigene Pharmaceutical Services Ltd. (Aurigene), a global contract research, development, and manufacturing services organization (CRDMO), and Vipergen ApS, a niche small-molecule drug discovery service provider specialized in DEL technologies, entered into a strategic partnership.
Read MoreAurigene.AI combines advanced physics-based simulation, generative and predictive AI models, and CADD (Computer-Aided Drug Design) in one platform, allowing users to pick the appropriate algorithms for a given application. The modular platform also consists of a meticulously curated database of 180 million compounds and 1.6 million validated bioassay data points. This database is ever-expanding and serves as training data for the platform.
Read MoreAurigene Pharmaceutical Services, a contract research, development, and manufacturing services organisation and a step-down subsidiary of Dr Reddy's Laboratories, has decided to establish a development and manufacturing facility focused on niche areas like therapeutic proteins, antibodies, and viral vectors in Hyderabad.
Read MoreAurigene is investing $40m Mn USD in an R&D and pilot scale facility as a first step towards a series of strategic investments. Complemented by exclusive access to large-scale GMP commercial manufacturing capacity including fill-finish.
Read MorePotential partnership to explore new therapeutic solutions and serve unmet needs of patients in Neglected Tropical Diseases in LMICs and beyond.
Read MoreAurigene has been established as a wholly-owned subsidiary of Dr. Reddy’s through the merger of Aurigene Discovery Services and Dr. Reddy’s Custom Pharma Services (CPS). The launch of the brand happened during the pandemic and it is therefore the first opportunity for the team to exhibit the new brand to its customers.
Read MoreAurigene Pharmaceutical Services Limited, a wholly-owned subsidiary of Dr. Reddy’s expands its existing discovery and development capacities with the inauguration of a biotherapeutics discovery facility in Hyderabad, India.
Read MoreDeepMatter Group Plc (AIM: DMTR, “Deepmatter”, the “Group”), the international digital chemistry data company, has signed a trials agreement with Aurigene Pharmaceutical Services Limited (“Aurigene Pharmaceutical Services”), based in Hyderabad, India, to supply its DigitalGlassware® platform.
Read MoreJUNE 18, 2024
MAY 16, 2024
MAY 15, 2024
AUGUST 23, 2023
MAY 19, 2023
NOVEMBER 16, 2023
JUNE 28, 2022
JULY 02, 2021
JANUARY 04, 2021
JANUARY 04, 2021
JANUARY 04, 2021
FEBRUARY 23, 2021
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market